文献速递类风湿关节炎

托珠单抗单药与阿达木单抗联合甲氨蝶呤对类风湿关节炎骨侵蚀修复的比较

Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2019-05-29

REBONE研究为前瞻性非随机观察性研究,纳入活动性侵蚀性RA且对MTX应答不足的患者,分别接受托珠单抗单药或阿达木单抗联合MTX治疗52周。高分辨率外周定量CT显示托珠单抗组掌骨头和桡骨骨侵蚀体积显著减小,而阿达木单抗联合MTX组无显著变化。提示IL-6是RA关节骨稳态紊乱的核心因子,托珠单抗单药对已有骨侵蚀的修复作用优于阿达木单抗联合MTX。

要点

  • 托珠单抗单药治疗52周可显著减小掌骨头和桡骨骨侵蚀体积(p<0.001)。
  • 阿达木单抗联合MTX治疗52周骨侵蚀体积无显著变化(p=0.77)。
  • 两组疾病活动度均显著降低,但骨侵蚀修复作用不同。

核心结论

  • 托珠单抗单药对已有骨侵蚀的修复作用比阿达木单抗联合MTX更明显。
  • IL-6是RA患者关节骨稳态紊乱的核心因子。

研究设计与样本

  • 前瞻性非随机观察性研究,纳入活动性侵蚀性RA且对MTX应答不足的患者。
  • 托珠单抗单药组33例,阿达木单抗联合MTX组33例,治疗52周。
  • 基线及52周时采用高分辨率外周定量CT评估掌骨头和桡骨骨侵蚀体积。
  • 每12周用CDAI、SDAI和DAS28-ESR监测临床应答。

主要发现

  • 托珠单抗组DAS28-ESR从基线6.2±0.5降至52周2.3±1.0,阿达木单抗联合MTX组从6.3±0.6降至2.8±1.2。
  • 托珠单抗组掌骨头和桡骨骨侵蚀体积显著减小(p<0.001),阿达木单抗联合MTX组无显著变化(p=0.77)。
  • 托珠单抗组骨侵蚀体积平均减少:掌骨头-1.0±1.1 mm³,桡骨-3.3±5.9 mm³。
  • 阿达木单抗联合MTX组骨侵蚀体积平均减少:掌骨头-0.05±0.9 mm³,桡骨-0.08±4.1 mm³。

临床怎么用

  • 对于活动性侵蚀性RA且对MTX应答不足的患者,托珠单抗单药可能有助于修复已有骨侵蚀。
  • 阿达木单抗联合MTX虽能控制疾病活动度,但未显示骨侵蚀修复作用。

局限性

  • 研究为非随机观察性设计,样本量较小(每组33例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the effects of interleukin-6 (IL-6) receptor and tumour necrosis factor inhibition on inducing repair of existing bone erosions in patients with very early rheumatoid arthritis (RA). METHODS: Prospective non-randomised observational study in patients with active erosive RA with inadequate response to methotrexate (MTX) receiving either tocilizumab (TOC) monotherapy or adalimumab (ADA) with MTX for 52 weeks. Erosion volumes were assessed in metacarpal heads (MCH) and the radius by high-resolution peripheral quantitative CT at baseline and after 52 weeks. Clinical response was monitored using Clinical Disease Activity Index, Simple Disease Activity Index and Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) scores every 12 weeks. RESULTS: TOC (N=33) and ADA/MTX (N=33) treatment groups were balanced for age, sex, body mass index, comorbidities, disease and activity, functional state, autoantibody status, baseline bone damage and baseline bone biomarkers. Both TOC (DAS28-ESR: baseline: 6.2±0.5; 52 weeks: 2.3±1.0) and ADA/MTX (6.3±0.6; 2.8±1.2) significantly reduced disease activity. Erosion volumes significantly decreased in the MCH and radius of patients with RA treated with TOC (p<0.001) but not in patients treated with ADA/MTX (p=0.77), where they remained stable in size. Mean decrease in erosion volume in TOC-treated patients was -1.0±1.1 mm3 and -3.3±5.9 mm3 in the MCH and radius of TOC-treated patients, respectively, and -0.05±0.9 mm3 and -0.08±4.1 mm3 in patients treated with ADA/MTX. CONCLUSIONS: The REBONE study shows that TOC monotherapy achieves more pronounced repair of existing bone erosions than ADA/MTX. Hence, IL-6 is a central factor for the disturbed bone homeostasis in the joints of patients with RA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Finzel S, Kraus S, Figueiredo CP, et al. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Ann Rheum Dis. 2019. PMID: 31142474. doi:10.1136/annrheumdis-2018-214894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。